Through analyses of a variety of human KRAS, NRAS or BRAF mutant cell lines from different tumor entities (CRC, NSCLC, PDAC, RMS) we further showed that these principles also apply to the complex genetic backgrounds that arise during human RAS-pathway driven cancer development. This evidence concerns the gene NRAS and non-small cell lung carcinoma.